PATIENT CARD

MYQORZO® ▼
(aficamten)

PC7132756

Patient instructions: Carry this card with you **at all times**. Tell any healthcare professional who sees you that you are taking aficamten and show this card to them.

MYQORZO (aficamten) is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Refer to the package leaflet for more information or contact Cytokinetics Medical Information at medinfo.europe@cytokinetics.com or 0808 168 6468.

Safety information for patients of childbearing potential:

- *The effects of MYQORZO on an unborn baby are not fully known.*
- Women of childbearing potential need to use effective contraception during treatment.
- Tell your doctor immediately if you are pregnant, think you may be pregnant or plan to become pregnant.
- Your doctor will discuss with you the potential risks of taking this medicine during pregnancy and decide if the treatment should be started or continued.
- If you are treated with MYQORZO during pregnancy, your doctor will carefully monitor you and your baby's heart function by doing echocardiograms. If there is a change in you or your baby's heart function, your doctor may adjust your dose or stop the treatment.

Safety information for all patients:

- MYQORZO (aficamten) may increase your risk of heart failure due to systolic dysfunction, a condition where the heart cannot pump with enough force and which can be life-threatening.
- Tell your doctor **immediately** if you experience new or worsening irregular heartbeat (arrhythmia), shortness of breath, chest pain, tiredness, leg swelling or serious infection.
- It is very important to have echocardiogram appointments, because your doctor needs to check the effect of MYQORZO on your heart.
- Do not start, stop or change any medicines (including prescription and those available over-the-counter) or herbal supplements without consulting your prescriber of MYQORZO (aficamten).

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may experience via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Side effects should also be reported to Cytokinetics Medical Information at medinfo.europe@cytokinetics.com or 0808 168 6468.

Please complete this section or ask your prescriber of aficamten to complete it.

Patient's name: _____

_____

Name of prescriber: _____

_____

Office phone number: _____

_____

After-hours phone number: _____

_____

Hospital name (if applicable): _____

_____